Drug intelligence / Profile preview

SIPI-2011

Development stage: Unknown

Overview

SIPI-2011 is a novel small molecule antiarrhythmic agent developed by Jiangsu Kanion Pharmaceutical in collaboration with the Shanghai Institute of Pharmaceutical Industry (SIPI). It is designed as a multi-ion channel blocker, primarily targeting potassium, sodium, and calcium channels to treat various forms of ventricular arrhythmias, including premature ventricular contractions (PVC) and non-sustained ventricular tachycardia (NSVT). By inhibiting multiple cardiac ion channels, SIPI-2011 aims to provide the broad}

Beyond the preview

Go deeper on SIPI-2011.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SIPI-2011.

Explore the full profile